



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## MANS peptide

<b>Cat. No.:</b>	HY-P10218
<b>CAS No.:</b>	479482-23-0
<b>Molecular Formula:</b>	C <sub>111</sub> H <sub>184</sub> N <sub>30</sub> O <sub>35</sub>
<b>Molecular Weight:</b>	2498.83
<b>Sequence:</b>	{Myristic acid-Gly}-Ala-Gln-Phe-Ser-Lys-Thr-Ala-Ala-Lys-Gly-Glu-Ala-Ala-Ala-Glu-Arg-Pro-Gly-Glu-Ala-Ala-Val-Ala
<b>Sequence Shortening:</b>	{Myristic acid-Gly}-AQFSKTAAKGEAAAERPGEAAVA
<b>Target:</b>	PKC
<b>Pathway:</b>	Epigenetics; TGF-beta/Smad
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis <sup>[1]</sup> .																
<b>In Vitro</b>	<p>MANS peptide (0-100 μM, 12-24 h) inhibits migration and invasion of lung cancer cells CL1-0/F3, CL1-5, PC9 and A549 without causing toxicity to normal cells<sup>[1]</sup>.</p> <p>MANS peptide (0-100 μM, 16 h) inhibits MARCKS phosphorylation and PI3K and AKT phosphorylation, leads to downstream changes in Slug and E-cadherin expression levels, prevents the loss of cell-cell adhesion, alters epithelial-mesenchymal transition (EMT) characteristics of cancer cells, and thus decreases tumor metastasis<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>CL1-0/F3, CL1-5 and PC9</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>12-24 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited migration.</td> </tr> </table> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>CL1-0/F3, CL1-5, PC9 and NHBE</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>16 h</td> </tr> <tr> <td>Result:</td> <td>Upregulated levels of E-cadherin, downregulated levels of Slug. Suppressed MARCKS phosphorylation and AKT/Slug pathway.</td> </tr> </table>	Cell Line:	CL1-0/F3, CL1-5 and PC9	Concentration:	0-100 μM	Incubation Time:	12-24 h	Result:	Inhibited migration.	Cell Line:	CL1-0/F3, CL1-5, PC9 and NHBE	Concentration:	0-100 μM	Incubation Time:	16 h	Result:	Upregulated levels of E-cadherin, downregulated levels of Slug. Suppressed MARCKS phosphorylation and AKT/Slug pathway.
Cell Line:	CL1-0/F3, CL1-5 and PC9																
Concentration:	0-100 μM																
Incubation Time:	12-24 h																
Result:	Inhibited migration.																
Cell Line:	CL1-0/F3, CL1-5, PC9 and NHBE																
Concentration:	0-100 μM																
Incubation Time:	16 h																
Result:	Upregulated levels of E-cadherin, downregulated levels of Slug. Suppressed MARCKS phosphorylation and AKT/Slug pathway.																
<b>In Vivo</b>	MANS peptide (50 nmol/injection, ip, every 3 days for 6 injection) inhibits tumor metastasis, without affecting tumorigenesis in PC9 xenograft NOD/SCID mice model <sup>[1]</sup> .																

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID mice model <sup>[1]</sup>
Dosage:	50 nmol/injection
Administration:	Ip, every 3 days for 6 times
Result:	Suppressed micrometastatic lesions.

---

## REFERENCES

[1]. Chen CH, et al., A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. *Oncogene*. 2014 Jul 10;33(28):3696-706.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA